Latest Illumina Inc (ILMN) Headlines Insider Tr
Post# of 63
Posted On: 03/13/2014 9:50:01 AM
Latest Illumina Inc (ILMN) Headlines
Insider Trading Alert - ITMN, M And ILMN Traded By Insiders
at The Street - Wed Mar 12, 9:45AM CDT
Stocks with insider trader activity include ITMN, M and ILMN
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
Business Wire - Mon Mar 10, 5:30AM CDT
Illumina, Inc. (NASDAQ:ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.
Watch for Illumina to Potentially Rebound After Falling 1.76% Yesterday
Comtex SmarTrend(R) - Fri Mar 07, 3:47PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $164.02 to a high of $174.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $170.65 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Illumina to Potentially Rebound after Yesterday's 1.76% Sell Off
Comtex SmarTrend(R) - Fri Mar 07, 3:46PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $164.02 to a high of $174.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $170.65 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
3 Reasons to Buy 2014's Smartest Company
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Looking for one of the new year's fastest-rising stocks? Look no further than Illumina , the gene-sequencing giant that's taken the market by storm, gaining more than 250% over the past two years. However, that rapid climb has given way to caution:...
Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating
M2 - Thu Mar 06, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5lxv6/global) has announced the addition of the "Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating" report to their offering. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. As a result of declining budgets for R&D, biotechnology companies and other organizations are seeking ways to increase efficiency by outsourcing bioinformatics to effectively support their R&D activities at less cost. Also, outsourcing may be an increasingly viable option for research organizations which lack the requisite computational infrastructure and informatics expertise for bioinformatics tools in house. Outsourcing the services to a third-party vendor can allow an organization to refocus on key projects that contribute to increasing the effectiveness of its R&D and shorten development-to-launch timelines. One of the major drivers in this market is the decreasing cost of genetic sequencing. This reduction in cost is a result of the development of tools and technologies as well as the improvements in processes made by genomics researchers. The report states that one of the major challenges in the market is the growing complexity in using bioinformatics tools and the consequent need for proper training and guidance to use these tools properly and efficiently. The key vendors dominating this market space are: - Accelrys Inc. - Affymetrix Inc. - Agilent Technologies Inc. - CLCbio A/S - Illumina Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Products and Services 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/r5lxv6/global
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals
PR Newswire - Wed Mar 05, 12:08PM CST
Editor Note: For more information about this release, please scroll to bottom.
How Craig Venter Plans to Challenge Google in the Race to Enhance Human Health
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Mar 04, 8:13PM CST
" In this world nothing can be said to be certain, except death and taxes. " -- Benjamin Franklin It will be awfully difficult to challenge the natural cellular processes that contribute to the death of a living organism, but no one said we...
The Hayner Group and Amster-Vairo Announce Partnership at Israel Dealmakers Summit
PR Newswire - Tue Mar 04, 5:00AM CST
The Hayner Group and Amster-Vairo and Associates announce a new partnership at the Israel Dealermakers Summit taking place in New York on March 4 and 5th. This partnership combines the skills and expertise of both companies, resulting in a more comprehensive offering of business services from seed stage through mid-market companies, with a specialty in the technology sector.
PacBio, the Post-Hype Sleeper of Genomics
Luke Timmerman, The Motley Fool - Motley Fool - Mon Mar 03, 1:22PM CST
Hype and biotech go hand in hand, but genomics takes exaggeration up a few extra notches . When genomics companies fail, they tend to crash especially hard. Yet every now and then, a company that is monumentally hyped falls flat and then figures out...
Global Proteomics Market 2012-2016: One of the Main Drivers in This Market Is the Increasing Demand for Personalized Medicines
M2 - Fri Feb 28, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/dn2hwq/global_proteomics) has announced the addition of the "Global Proteomics Market 2012-2016" report to their offering. The analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market. The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp. The other vendors mentioned in the report are Sigma-Aldrich Corp., Roche Diagnostics Corp., Betcon Dickinson and Co., Affymetrix Inc., Shimadzu Corp., Bio Rad Laboratories Inc., Illumina Inc., Abbott Laboratories, GE Healthcare Ltd., Perkin Elmer Inc., Xencor Inc., Cellzome AG, Waters Corp., Dionex Corp., and Bruker Daltonics Inc. Commenting on the report, an analyst from the Healthcare team said: ''One of the recent trends being witnessed in the Global Proteomics market is the growing popularity of proteomic analysis as compared to genomic analysis. Both genomics and proteomics find application in drug discovery, disease diagnosis, and drug development. Genomics is the study of the genes or DNA of an organism. Proteomics, which was introduced after genomics, has become more popular because it offers more benefits than genomics. For instance, proteomic analysis is faster and more effective in terms of data analysis than genomic analysis. Thus, there is a considerable shift from genomics to proteomics for disease diagnosis and drug development. This trend augers well for the growth of the Global Proteomics market during the forecast period.'' For more information visit http://www.researchandmarkets.com/research/dn...proteomics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
'Mad Money' Lightning Round: Stay Away From Sohu.com
at The Street - Fri Feb 28, 5:00AM CST
Cramer likes Cemex and Precision Castparts and thinks Illumina can go higher.
Jim Cramer's 'Mad Money' Recap: Don't Settle For Average
at The Street - Thu Feb 27, 6:47PM CST
Today's market shows how a little homework can allow investors to do so much better than index funds, Cramer says.
Global Gene Expression (DNA Microarray, Real-Time PCR, Next Generation Sequencing) Analysis Market 2014-2018
M2 - Thu Feb 27, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqf4hv/gene_expression) has announced the addition of the "Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018" report to their offering. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4% Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications. Some of the applications using gene expression analysis are pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. However, the high cost of instruments and the need for skilled professionals to operate these highly sophisticated systems are factors that are hindering the market. The global gene expression analysis market witnesses high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographic expansions related to endoscopy products) to increase their market shares and to establish a strong foothold in the global market. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares. Scope of the Report - Market Penetration: Comprehensive information on the product portfolios and services offered by the top 10 players in the gene expression analysis market. The report analyzes instruments (by technology), consumables, and services - Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the gene expression analysis market - Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various gene expression analysis products across geographies - Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the gene expression analysis market - Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the gene expression analysis market Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology 6 Gene Expression Analysis Consumables Market, By Product 7 Gene Expression Analysis Services Market, By Product 8 Gene Expression Analysis Market, By Application 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/dq...expression
DNA blood tests show prenatal screening promise
By MARILYNN MARCHIONE - AP - Wed Feb 26, 5:09PM CST
A DNA test of a pregnant woman's blood is more accurate than current methods of screening for Down syndrome and other common disorders, new research finds. If other studies bear this out, it could transform prenatal care by giving a more reliable, non-invasive way to detect these problems very early in pregnancy.
Illumina's Non-Invasive verifi(R) Prenatal Test Using cfDNA Significantly Reduces False Positive Rate of Fetal Aneuploidy Detection Compared to Current Standard Pregnancy Screening Practices
Business Wire - Wed Feb 26, 4:00PM CST
Illumina, Inc. (NASDAQ: ILMN) today announced that in a direct comparison of non-invasive prenatal testing (NIPT) using cell free DNA (cfDNA) to standard prenatal aneuploidy screening in a general obstetrical population, the verifi(R) prenatal test(1) significantly reduced the rate of false positive results for the detection of fetal trisomies 21 and 18. In addition, the study demonstrated that the verifi(R) prenatal test performs consistently well in all pregnant women, regardless of their risk level for fetal aneuploidy.
MOgene LC Announces Illumina CSPro Certification for Sequencing
Marketwire - Wed Feb 26, 12:05PM CST
MOgene LC announced today that it has successfully completed Illumina CSPro(TM) certification for sequencing on HiSeq and MiSeq, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
The Next Generation Sequencing (NGS) Market is Poised to Reach $2.7 billion by 2017
M2 - Wed Feb 26, 8:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/4mskzv/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market - Global Forecast to 2017" report to their offering. This research report categorizes and analyzes the global Next Generation Sequencing (NGS) market on the basis of steps in the NGS workflow and NGS applications. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario. The next generation sequencing (NSG) market is rapidly evolving with a large number of developments taking place to increase accuracy and speed, and reduce costs of sequencing. It is the fastest-growing and most lucrative segment in the genomics space with an estimated growth of 16.3%. The global NGS market was valued at $1.3 billion in 2012 and is poised to reach $2.7 billion by 2017. By supporting genomics research, various government bodies like NHGRI (National Human Genome Research Institute, U.S.) and Biotechnology and Biological Sciences Research Council (BBSRC, U.K.) are increasing the adoption of high-throughput sequencing platforms. Key Findings: - The NGS pre-sequencing (sample - preparation) segment represents a promising area in the overall market owing to the need for automation and standardized solutions for sample preparation. The market for sequencing platforms has been very dynamic. Some revolutionary platforms like GA IIx (Illumina) and SOLiD Series (Life Technologies) have taken a setback and newer platforms like MiSeq and Ion Torrent Proton are gaining market dominance. - Along with large research and academic institutions that serve as a key end-user for the NGS market, NGS technologies are recently being developed for use in clinical set-ups and presently much of the NGS effort is focused on cancer. - The factors driving the NGS market include decreasing costs, improved turnaround time, increase in number of applications, and replacement of microarray applications by NGS. Personalized medicine and biomarker discovery open avenues for investments, thus offering a growth opportunity for the NGS market. However, the causes for hindrance to growth will be the high reliability on grants by research institutes, accuracy and standardization concerns, data storage problems, and issues in interpretation of complex data. Companies Mentioned: - Agilent Technologies, Inc - BGI (Beijing Genomics Institute) - Biomatters, Ltd - CLC Bio - Dnastar, Inc - EMC Corporation - GATC biotech AG - Genomatix Software GMBH - Illumina, Inc - Knome, Inc - Life Sciences Corporation (A Roche Company) - Life Technologies Corporation - Macrogen, Inc - Ocimum Biosolutions, Ltd - Oxford Nanorpore Technologies, Ltd - Pacific Biosciences - Partek Incorporated - Perkinelmer, Inc - Qiagen NV - Strand Life Sciences Pvt Ltd For more information visit http://www.researchandmarkets.com/research/4m...generation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Insider Trading Alert - ITMN, M And ILMN Traded By Insiders
at The Street - Wed Mar 12, 9:45AM CDT
Stocks with insider trader activity include ITMN, M and ILMN
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
Business Wire - Mon Mar 10, 5:30AM CDT
Illumina, Inc. (NASDAQ:ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.
Watch for Illumina to Potentially Rebound After Falling 1.76% Yesterday
Comtex SmarTrend(R) - Fri Mar 07, 3:47PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $164.02 to a high of $174.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $170.65 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Illumina to Potentially Rebound after Yesterday's 1.76% Sell Off
Comtex SmarTrend(R) - Fri Mar 07, 3:46PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $164.02 to a high of $174.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $170.65 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
3 Reasons to Buy 2014's Smartest Company
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Looking for one of the new year's fastest-rising stocks? Look no further than Illumina , the gene-sequencing giant that's taken the market by storm, gaining more than 250% over the past two years. However, that rapid climb has given way to caution:...
Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating
M2 - Thu Mar 06, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5lxv6/global) has announced the addition of the "Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating" report to their offering. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. As a result of declining budgets for R&D, biotechnology companies and other organizations are seeking ways to increase efficiency by outsourcing bioinformatics to effectively support their R&D activities at less cost. Also, outsourcing may be an increasingly viable option for research organizations which lack the requisite computational infrastructure and informatics expertise for bioinformatics tools in house. Outsourcing the services to a third-party vendor can allow an organization to refocus on key projects that contribute to increasing the effectiveness of its R&D and shorten development-to-launch timelines. One of the major drivers in this market is the decreasing cost of genetic sequencing. This reduction in cost is a result of the development of tools and technologies as well as the improvements in processes made by genomics researchers. The report states that one of the major challenges in the market is the growing complexity in using bioinformatics tools and the consequent need for proper training and guidance to use these tools properly and efficiently. The key vendors dominating this market space are: - Accelrys Inc. - Affymetrix Inc. - Agilent Technologies Inc. - CLCbio A/S - Illumina Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Products and Services 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/r5lxv6/global
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals
PR Newswire - Wed Mar 05, 12:08PM CST
Editor Note: For more information about this release, please scroll to bottom.
How Craig Venter Plans to Challenge Google in the Race to Enhance Human Health
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Mar 04, 8:13PM CST
" In this world nothing can be said to be certain, except death and taxes. " -- Benjamin Franklin It will be awfully difficult to challenge the natural cellular processes that contribute to the death of a living organism, but no one said we...
The Hayner Group and Amster-Vairo Announce Partnership at Israel Dealmakers Summit
PR Newswire - Tue Mar 04, 5:00AM CST
The Hayner Group and Amster-Vairo and Associates announce a new partnership at the Israel Dealermakers Summit taking place in New York on March 4 and 5th. This partnership combines the skills and expertise of both companies, resulting in a more comprehensive offering of business services from seed stage through mid-market companies, with a specialty in the technology sector.
PacBio, the Post-Hype Sleeper of Genomics
Luke Timmerman, The Motley Fool - Motley Fool - Mon Mar 03, 1:22PM CST
Hype and biotech go hand in hand, but genomics takes exaggeration up a few extra notches . When genomics companies fail, they tend to crash especially hard. Yet every now and then, a company that is monumentally hyped falls flat and then figures out...
Global Proteomics Market 2012-2016: One of the Main Drivers in This Market Is the Increasing Demand for Personalized Medicines
M2 - Fri Feb 28, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/dn2hwq/global_proteomics) has announced the addition of the "Global Proteomics Market 2012-2016" report to their offering. The analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market. The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp. The other vendors mentioned in the report are Sigma-Aldrich Corp., Roche Diagnostics Corp., Betcon Dickinson and Co., Affymetrix Inc., Shimadzu Corp., Bio Rad Laboratories Inc., Illumina Inc., Abbott Laboratories, GE Healthcare Ltd., Perkin Elmer Inc., Xencor Inc., Cellzome AG, Waters Corp., Dionex Corp., and Bruker Daltonics Inc. Commenting on the report, an analyst from the Healthcare team said: ''One of the recent trends being witnessed in the Global Proteomics market is the growing popularity of proteomic analysis as compared to genomic analysis. Both genomics and proteomics find application in drug discovery, disease diagnosis, and drug development. Genomics is the study of the genes or DNA of an organism. Proteomics, which was introduced after genomics, has become more popular because it offers more benefits than genomics. For instance, proteomic analysis is faster and more effective in terms of data analysis than genomic analysis. Thus, there is a considerable shift from genomics to proteomics for disease diagnosis and drug development. This trend augers well for the growth of the Global Proteomics market during the forecast period.'' For more information visit http://www.researchandmarkets.com/research/dn...proteomics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
'Mad Money' Lightning Round: Stay Away From Sohu.com
at The Street - Fri Feb 28, 5:00AM CST
Cramer likes Cemex and Precision Castparts and thinks Illumina can go higher.
Jim Cramer's 'Mad Money' Recap: Don't Settle For Average
at The Street - Thu Feb 27, 6:47PM CST
Today's market shows how a little homework can allow investors to do so much better than index funds, Cramer says.
Global Gene Expression (DNA Microarray, Real-Time PCR, Next Generation Sequencing) Analysis Market 2014-2018
M2 - Thu Feb 27, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqf4hv/gene_expression) has announced the addition of the "Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018" report to their offering. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4% Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications. Some of the applications using gene expression analysis are pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. However, the high cost of instruments and the need for skilled professionals to operate these highly sophisticated systems are factors that are hindering the market. The global gene expression analysis market witnesses high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographic expansions related to endoscopy products) to increase their market shares and to establish a strong foothold in the global market. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares. Scope of the Report - Market Penetration: Comprehensive information on the product portfolios and services offered by the top 10 players in the gene expression analysis market. The report analyzes instruments (by technology), consumables, and services - Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the gene expression analysis market - Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various gene expression analysis products across geographies - Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the gene expression analysis market - Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the gene expression analysis market Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology 6 Gene Expression Analysis Consumables Market, By Product 7 Gene Expression Analysis Services Market, By Product 8 Gene Expression Analysis Market, By Application 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/dq...expression
DNA blood tests show prenatal screening promise
By MARILYNN MARCHIONE - AP - Wed Feb 26, 5:09PM CST
A DNA test of a pregnant woman's blood is more accurate than current methods of screening for Down syndrome and other common disorders, new research finds. If other studies bear this out, it could transform prenatal care by giving a more reliable, non-invasive way to detect these problems very early in pregnancy.
Illumina's Non-Invasive verifi(R) Prenatal Test Using cfDNA Significantly Reduces False Positive Rate of Fetal Aneuploidy Detection Compared to Current Standard Pregnancy Screening Practices
Business Wire - Wed Feb 26, 4:00PM CST
Illumina, Inc. (NASDAQ: ILMN) today announced that in a direct comparison of non-invasive prenatal testing (NIPT) using cell free DNA (cfDNA) to standard prenatal aneuploidy screening in a general obstetrical population, the verifi(R) prenatal test(1) significantly reduced the rate of false positive results for the detection of fetal trisomies 21 and 18. In addition, the study demonstrated that the verifi(R) prenatal test performs consistently well in all pregnant women, regardless of their risk level for fetal aneuploidy.
MOgene LC Announces Illumina CSPro Certification for Sequencing
Marketwire - Wed Feb 26, 12:05PM CST
MOgene LC announced today that it has successfully completed Illumina CSPro(TM) certification for sequencing on HiSeq and MiSeq, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
The Next Generation Sequencing (NGS) Market is Poised to Reach $2.7 billion by 2017
M2 - Wed Feb 26, 8:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/4mskzv/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market - Global Forecast to 2017" report to their offering. This research report categorizes and analyzes the global Next Generation Sequencing (NGS) market on the basis of steps in the NGS workflow and NGS applications. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario. The next generation sequencing (NSG) market is rapidly evolving with a large number of developments taking place to increase accuracy and speed, and reduce costs of sequencing. It is the fastest-growing and most lucrative segment in the genomics space with an estimated growth of 16.3%. The global NGS market was valued at $1.3 billion in 2012 and is poised to reach $2.7 billion by 2017. By supporting genomics research, various government bodies like NHGRI (National Human Genome Research Institute, U.S.) and Biotechnology and Biological Sciences Research Council (BBSRC, U.K.) are increasing the adoption of high-throughput sequencing platforms. Key Findings: - The NGS pre-sequencing (sample - preparation) segment represents a promising area in the overall market owing to the need for automation and standardized solutions for sample preparation. The market for sequencing platforms has been very dynamic. Some revolutionary platforms like GA IIx (Illumina) and SOLiD Series (Life Technologies) have taken a setback and newer platforms like MiSeq and Ion Torrent Proton are gaining market dominance. - Along with large research and academic institutions that serve as a key end-user for the NGS market, NGS technologies are recently being developed for use in clinical set-ups and presently much of the NGS effort is focused on cancer. - The factors driving the NGS market include decreasing costs, improved turnaround time, increase in number of applications, and replacement of microarray applications by NGS. Personalized medicine and biomarker discovery open avenues for investments, thus offering a growth opportunity for the NGS market. However, the causes for hindrance to growth will be the high reliability on grants by research institutes, accuracy and standardization concerns, data storage problems, and issues in interpretation of complex data. Companies Mentioned: - Agilent Technologies, Inc - BGI (Beijing Genomics Institute) - Biomatters, Ltd - CLC Bio - Dnastar, Inc - EMC Corporation - GATC biotech AG - Genomatix Software GMBH - Illumina, Inc - Knome, Inc - Life Sciences Corporation (A Roche Company) - Life Technologies Corporation - Macrogen, Inc - Ocimum Biosolutions, Ltd - Oxford Nanorpore Technologies, Ltd - Pacific Biosciences - Partek Incorporated - Perkinelmer, Inc - Qiagen NV - Strand Life Sciences Pvt Ltd For more information visit http://www.researchandmarkets.com/research/4m...generation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Illumina Inc. (ILMN) Stock Research Links
Scroll down for more posts ▼